Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20501647
Boulbes D, et al. (2010) Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Mol Cancer Res 8, 896-906 20501647
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical), MDA-MB-435 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE mTOR (human)
Comments:  mTor activity associated with Rictor.
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
serum increase
serum HRas (human) augment treatment-induced increase
IGF-1 increase
IGF-1 HRas (human) augment treatment-induced increase
IGF-1 PIK3CB (human) augment treatment-induced increase
HRas (human) increase
IGF-1 increase
mTOR (human) increase mTor shRNA decreases
IGF-1 increase
ILK (human) increase ILK shRNA decreases
LY294002 IGF-1 inhibit treatment-induced increase
rapamycin increase

S2481-p - mTOR (human)
Modsite: tVPEsIHsFIGDGLV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2481‑p, mTOR (mouse): S2481‑p, mTOR (rat): S2481‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical), MDA-MB-435 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
serum HRas (human) augment treatment-induced increase
IGF-1 increase
IGF-1 HRas (human) augment treatment-induced increase
IGF-1 PIK3CB (human) augment treatment-induced increase
HRas (human) increase
IGF-1 increase
ILK (human) increase ILK shRNA decreases
LY294002 IGF-1 inhibit treatment-induced increase
rapamycin decrease

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical), MDA-MB-435 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
rapamycin decrease

T1135-p - RICTOR (human)
Modsite: NRRIRtLtEPsVDFN SwissProt Entrez-Gene
Orthologous residues
RICTOR (human): T1135‑p, RICTOR iso3 (human): T1135‑p, RICTOR iso4 (human): , RICTOR (mouse): T1135‑p, RICTOR (rat): T1120‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical), MDA-MB-435 (breast cell)
Cellular systems studied:  cell lines, primary cells
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
serum increase
serum HRas (human) augment treatment-induced increase
IGF-1 increase
IGF-1 HRas (human) augment treatment-induced increase
IGF-1 PIK3CB (human) augment treatment-induced increase
HRas (human) increase
IGF-1 increase
mTOR (human) increase mTor shRNA decreases
IGF-1 increase
ILK (human) increase ILK shRNA decreases
LY294002 IGF-1 inhibit treatment-induced increase
rapamycin decrease

S1177-p - RICTOR (human)
Modsite: EDtGstPsIGENDLk SwissProt Entrez-Gene
Orthologous residues
RICTOR (human): S1177‑p, RICTOR iso3 (human): S1177‑p, RICTOR iso4 (human): , RICTOR (mouse): S1176‑p, RICTOR (rat): S1162‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical), MDA-MB-435 (breast cell)
Cellular systems studied:  cell lines, primary cells
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
serum no change compared to control
serum HRas (human) no change compared to control
IGF-1 no change compared to control
IGF-1 HRas (human) no change compared to control

S473-p - Akt1 (mouse)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 no effect upon treatment-induced increase
Sin1 (human) increase Sin1 -/- MEFs inhibit
Sin1 (mouse) increase Sin1 -/- MEFs inhibit

T412-p - p70S6K (mouse)
Modsite: NQVFLGFtYVAPSVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 inhibit treatment-induced increase
IGF-1 Sin1 (mouse) no effect upon treatment-induced increase Sin1 -/- no effect
rapamycin Sin1 (mouse) no effect upon treatment-induced decrease Sin 1-/- no effect

T1135-p - RICTOR (mouse)
Modsite: NRRIRtLtEPsVDLN SwissProt Entrez-Gene
Orthologous residues
RICTOR (human): T1135‑p, RICTOR iso3 (human): T1135‑p, RICTOR iso4 (human): , RICTOR (mouse): T1135‑p, RICTOR (rat): T1120‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 inhibit treatment-induced increase
IGF-1 Sin1 (mouse) no effect upon treatment-induced increase Sin1 -/- no effect
rapamycin Sin1 (mouse) no effect upon treatment-induced decrease Sin 1-/- no effect

S1176-p - RICTOR (mouse)
Modsite: EDAGstPsIGENDLK SwissProt Entrez-Gene
Orthologous residues
RICTOR (human): S1177‑p, RICTOR iso3 (human): S1177‑p, RICTOR iso4 (human): , RICTOR (mouse): S1176‑p, RICTOR (rat): S1162‑p